High GILT expression and an active and intact MHC class II antigen presentation pathway are associated with improved survival in melanoma

Kenneth H. Buetow, Lydia R. Meador, Hari Menon, Yih Kuang Lu, Jacob Brill, Haiyan Cui, Denise J. Roe, David J. DiCaudo, K. Taraszka Hastings

Research output: Contribution to journalArticle


The MHC class I Ag presentation pathway in melanoma cells has a well-established role in immune-mediated destruction of tumors. However, the clinical significance of theMHCclass II Ag presentation pathway in melanoma cells is less clear. In Ag-presenting cells, IFN-γ-inducible lysosomal thiol reductase (GILT) is critical for MHC class II-restricted presentation of multiple melanoma Ags. Although not expressed in benign melanocytes of nevi, GILT and MHC class II expression is induced in malignant melanocytes in a portion of melanoma specimens. Analysis of The Cancer Genome Atlas cutaneous melanoma data set showed that high GILT mRNA expression was associated with improved overall survival. Expression of IFN-γ, TNF-α, and IL-1β was positively associated with GILT expression in melanoma specimens. These cytokines were capable of inducing GILT expression in human melanoma cells in vitro. GILT protein expression in melanocytes was induced in halo nevi, which are nevi undergoing immune-mediated regression, and is consistent with the association of GILT expression with improved survival in melanoma. To explore potential mechanisms of GILT's association with patient outcome, we investigated pathways related to GILT function and expression. In contrast to healthy skin specimens, in which the MHC class II pathway was nearly uniformly expressed and intact, there was substantial variation in the MHC class II pathway in the The Cancer Genome Atlas melanoma specimens. Both an active and intact MHC class II pathway were associated with improved overall survival in melanoma. These studies support a role for GILT and the MHC class II Ag presentation pathway in melanoma outcome.

Original languageEnglish (US)
Pages (from-to)2577-2587
Number of pages11
JournalJournal of Immunology
Issue number10
Publication statusPublished - Nov 15 2019


ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this